- Home
- AVNT vs DNLI Comparison
AVNT vs DNLI Comparison
Compare AVNT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNT | DNLI |
|---|---|---|
| Founded | 1927 | 2013 |
| Country | United States | United States |
| Employees | 9000 | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AVNT | DNLI |
|---|---|---|
| Price | $37.31 | $25.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $41.50 | $34.33 |
| AVG Volume (30 Days) | 979.9K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $3,835,500,000.00 | N/A |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | $3.48 | $408.85 |
| P/E Ratio | $61.15 | ★ N/A |
| Revenue Growth | ★ 1.71 | N/A |
| 52 Week Low | $27.48 | $12.58 |
| 52 Week High | $44.85 | $26.80 |
Technical Indicators
Market Signals| Indicator | AVNT | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 74.24 |
| Support Level | $35.35 | $18.07 |
| Resistance Level | $39.20 | N/A |
| Average True Range (ATR) | 1.14 | 1.15 |
| MACD | 0.02 | 0.24 |
| Stochastic Oscillator | 56.31 | 83.50 |
Price Performance
Historical ComparisonAbout AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two reportable segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The Color, Additives, and Inks segment and the distribution segment generate maximum revenue. Geographically, the company generates maximum revenue from the United States and Canada, followed by EMEA, Asia, and Latin America.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.